Adherence to Antiretroviral Therapy Among HIV-Infected Drug Users: A Meta-Analysis

被引:0
作者
Monica Malta
Monica M. F. Magnanini
Steffanie A. Strathdee
Francisco I. Bastos
机构
[1] Oswaldo Cruz Foundation,Social Science Department, Sergio Arouca School of Public Health (DCS/ENSP)
[2] Federal University of Rio de Janeiro (IESC/UFRJ),Institute of Public Health Studies
[3] San Diego (UCSD) School of Medicine,Division of International Health and Cross Cultural Medicine, Department of Family and Preventive Medicine at University of California
[4] Oswaldo Cruz Foundation,Health Information Laboratory, Center for Scientific and Technological Information (LIS/ICICT)
来源
AIDS and Behavior | 2010年 / 14卷
关键词
HIV; AIDS; Adherence; Drug use; Meta-analysis;
D O I
暂无
中图分类号
学科分类号
摘要
We conducted a meta-analysis of studies assessing adherence to highly active antiretroviral therapy (HAART) and a qualitative systematic review of factors associated with better HAART outcomes among HIV+ drug users (DU). Thirty-eight studies were considered, which analyzed 14,960 patients (11,394 HIV+ DU, 76.2%). Overall adherence (pooled percent of DU classified as adherent in each study) was 0.60 (95% CI: 0.52–0.68), similar to levels identified by studies conducted with HIV+ patients who are not drug users. Time frame used to measure adherence was an independent predictor of inter-study heterogeneity. The systematic review identified better HAART outcomes among former DU, those with less severe psychiatric conditions, those receiving opioid substitution therapy and/or psychosocial support. Patients initiating HAART with lower viral load and higher CD4 counts, and those without co-infections also had better treatment outcomes. Our findings suggest that HIV+ DU tend to be inappropriately assumed to be less adherent and unlikely to achieve desirable treatment outcomes, when compared to their non-DU cohort.
引用
收藏
页码:731 / 747
页数:16
相关论文
共 540 条
[1]  
Aceijas C(2006)Antiretroviral treatment for injecting DU in developing and transitional countries 1 year before the end of the “Treating 3 million by 2005. Making it happen. The WHO strategy” (“3 by 5”) Addiction (Abingdon, England) 101 1246-1253
[2]  
Oppenheimer E(2004)Developing a directly administered antiretroviral therapy intervention for HIV-infected DU: Implications for program replication Clinical Infectious Diseases 38 S376-S387
[3]  
Stimson GV(2001)Trust and the acceptance of and adherence to antiretroviral therapy Journal of Acquired Immune Deficiency Syndromes 28 47-58
[4]  
Ashcroft RE(2001)The revised CONSORT statement for reporting randomized trials: Explanation and elaboration Annals of Internal Medicine 134 663-694
[5]  
Matic S(2001)Antiretroviral therapy adherence and viral suppression in HIV-infected DU: Comparison of self-report and electronic monitoring Clinical Infectious Diseases 33 1417-1423
[6]  
Hickman M(2007)Factors associated with antiretroviral therapy adherence and medication errors among HIV-infected injection drug users Journal of Acquired Immune Deficiency Syndromes 46 S64-S71
[7]  
Altice FL(2008)Associations among correlates of schedule adherence to antiretroviral therapy (ART): A path analysis of a sample of crack cocaine using sexually active African-Americans with HIV infection AIDS Care 20 253-262
[8]  
Mezger JA(2001)Predictors of nonadherence to HIV-related medication regimens during methadone stabilization The American Journal on Addictions 10 69-78
[9]  
Hodges J(2006)Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression Clinical Infectious Diseases 43 939-941
[10]  
Bruce RD(1999)Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV cohort study Journal of Acquired Immune Deficiency Syndromes 21 114-119